{"id":"W2902172836","doi":"10.1021/acs.jmedchem.8b00843","title":"The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic","year":2018,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Institute of Allergy and Infectious Diseases; Government of Shandong Province; Science and Engineering Research Board; National Institutes of Health; Uppsala Universitet; National Natural Science Foundation of China; Department of Science and Technology, Ministry of Science and Technology, India; National Institute of Mental Health; European Molecular Biology Laboratory; Shandong University; Villum Fonden","keywords":"Efavirenz; Etravirine; Nevirapine; Rilpivirine; Reverse transcriptase; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Virology; Human immunodeficiency virus (HIV); Chemistry; Pharmacology; Medicine; Antiretroviral therapy; Viral load; RNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003348993,0.0005145376,0.0007485664,0.0007688939,0.001093047,0.004974407,0.0008500605,0.002028862,0.005437333],"category_scores_gemma":[0.002483804,0.000278293,0.0003532217,0.0008534685,0.002542714,0.004804955,0.002386073,0.004495276,0.002888151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001502028,"about_ca_system_score_gemma":0.003373121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006872503,"about_ca_topic_score_gemma":0.001256558,"domain_scores_codex":[0.9983846,0.0006048371,0.0001221961,0.0002186253,0.0005140066,0.0001556941],"domain_scores_gemma":[0.9983791,0.0005271705,0.0001629839,0.0001358962,0.0003571264,0.000437754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003432412,0.0005083549,0.002330892,0.00343424,0.00006211351,0.0004790091,0.001911322,0.0008789161,0.01491115,0.1080191,0.08104228,0.7860793],"study_design_scores_gemma":[0.00003132226,0.0008335626,0.001073082,0.000989526,0.00003113256,0.001478772,0.001005981,0.0003935365,0.004453551,0.02999051,0.9596824,0.00003652568],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01779767,0.7887335,0.01368722,0.1271538,0.003743658,0.0001006937,0.0003649808,0.000380178,0.04803837],"genre_scores_gemma":[0.1190453,0.7733833,0.04375725,0.03348438,0.003171565,0.0001315548,0.0004783988,0.0002233879,0.02632496],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005437333,"threshold_uncertainty_score":0.01818973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01457388499241907,"score_gpt":0.2861052684949563,"score_spread":0.2715313835025372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}